H/H Blood Group System: A Rare Blood Group

  • L. Reddenna Jagan’s College of Pharmacy
  • P. Venkatesh Jagan’s College of Pharmacy
  • K. Siva Kumar Nirmala College of Pharmacy
  • A Sai Keshava Reddy Nirmala College of Pharmacy
Keywords: Blood groups, Bombay phenotype, h/h blood group

Abstract

The subsistence of a human H/h genetic polymorphism was first recognized by the innovation of an individual devoid of the H antigen on red cells in Bombay who had antibodies in plasma reacting with all the red cells exhibiting the normal red cell ABO phenotypes. These persons were genetically termed as homozygous hh or Bombay phenotype. H-deficient Bombay phenotype is exceptional, since it occurs in about 1 in 10,000 individuals in India and 1 per 1,000,000 individuals in Europe. After the first report of Oh phenotype from Mumbai in 1952 by Bhende, numerous other workers detected this weird phenotype in India.The complexity with the Bombay phenotype is that the individuals having blood group of Bombay phenotype (Oh) can either receive autologous donation or blood from an individual of Bombay phenotype only; no other blood will match in case of an emergency blood transfusion. The aim of present study was to communicate the information about rare blood entity and to review the previous case reports.

Author Biographies

L. Reddenna, Jagan’s College of Pharmacy

Department of Pharmacy Practice,
 Jagan’s College of Pharmacy, Nellore,
Andhra Pradesh, India

P. Venkatesh, Jagan’s College of Pharmacy

Department of Pharmacy Practice,
 Jagan’s College of Pharmacy, Nellore,
Andhra Pradesh, India

K. Siva Kumar, Nirmala College of Pharmacy

Department of Pharmacy Practice,
Nirmala College of Pharmacy, Kadapa,
Andhra Pradesh, India

A Sai Keshava Reddy, Nirmala College of Pharmacy

Department of Pharmacy Practice,
Nirmala College of Pharmacy, Kadapa,
Andhra Pradesh, India

Published
2017-09-01
How to Cite
[1]
Reddenna, L., Venkatesh, P., Kumar, K.S. and Reddy, A.S.K. 2017. H/H Blood Group System: A Rare Blood Group. PharmaTutor. 5, 9 (Sep. 2017), 69-71.